{
  "id": 3368114,
  "title": "McKesson Stock Outlook: Is Wall Street Bullish or Bearish?",
  "url": "https://urgent.news/2026/08/24/mckesson-stock-outlook-is-wall-street-bullish-or-bearish",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-24T14:39:20.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/mckesson-stock-outlook-wall-street-143920869.html"
  },
  "original_language": "en",
  "account": "McKesson Corporation (MCK), a Texas-based healthcare giant distributing pharmaceuticals, medical supplies, and health-related products, has experienced mixed performance this year. While MCK's shares have gained 25.5% compared to the S&P 500's 20.5% increase, it underperformed the State Street SPDR S&P Health Care Services ETF (XHS) by a significant margin. The ETF has surged by 40.6% on a YTD basis, showcasing a stark contrast to MCK's single-digit returns.\n\nOperating revenues and adjusted earnings rose in Q1 2026, driven by strong volume growth in pharmaceutical distribution, specialty oncology, and heightened demand for GLP-1 weight-loss medications. However, profit margins suffered due to shifts in product mix, lower demand in primary care, and challenges in customer contracts. This disparity in performance highlights the challenges MCK faces in balancing top-line expansion with cost pressures and the slowing momentum of GLP-1 medications.\n\nDespite these hurdles, McKesson remains optimistic, boasting an impressive earnings surprise record. The company has beaten consensus estimates in four consecutive quarters, garnering a consensus strong buy rating from 19 analysts. Barclays PLC (BCS) analyst Glen Santangelo recently maintained an Overweight rating and lifted the price target to $1,000, indicating a potential 16.4% upside from current levels. The average price target of $976.24 represents a 13.7% premium to MCK's present valuation, with a Street-high target of $1,080 suggesting a more substantial 25.7% upside potential. As of the article's publication, Neha Panjwani disclosed no holdings in any of the mentioned securities.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}